Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics to Host Investor Day on Wednesday, December 7, 2016
Argos Therapeutics to Participate in 2016 BIO Investor Forum
Argos Therapeutics to Participate in 2016 Cell & Gene Meeting on the Mesa